Loading…
BRTX
BioRestorative Therapies, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 090655606
$0.20-3.35%Price as of Aug 29, 18:46 UTC · updated once a day, after the close
Key metrics
- Market cap
- $5.07M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.7x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.06
- ROE
- -241.14%
- Profit margin
- 0.00%
- Revenue growth
- -7.30%
- Beta
- 0.74
- 52-week high
- $1.86
- 52-week low
- $0.16
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -81.8% over 5Y.
today you would have $177.08▼ -82.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $23.50 | $1.43 | $1.74 | $2.75 | |
| P/S | 70.3x | 579.9x | 24.7x | 56.2x | 84.4x |
| P/B | 1.1x | 584.7x | 1.2x | 0.8x | 1.0x |
| EPS | -$1.58 | -$1.16 | -$2.47 | -$3.65 | |
| Profit margin | -5552.30% | -3959.40% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PCSAProcessa Pharmaceuticals, Inc. | $1.84 | 2.8x | — | — | -464.20% | $5.14M |
| AMIXAutonomix Medical, Inc. | $5.32 | — | 0.9x | — | -315.99% | $5.17M |
| MLECMoolec Science SA | $6.80 | — | 9.7x | — | — | $4.94M |
| POASPHAOS TECHNOLOGY HOLDINGS (CAYMAN) Ltd | $0.17 |
About the company
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
- 13
- Melville, United States
Company description provided by Yahoo Finance.